Diffuse Large B-Cell Lymphoma Primary CD20 positive Ann Arbor lymphoma staging system | Diffuse Large B-Cell Lymphoma Transformation CD20 positive Ann Arbor lymphoma staging system | Follicular Lymphoma Ann Arbor lymphoma staging system
Item
any stage, histologically confirmed cd20-positive primary or transformed diffuse large b cell lymphoma (dlbcl)or grade 3 follicular lymphoma (fl)
boolean
C0079744 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C3888518 (UMLS CUI [1,3])
C0432516 (UMLS CUI [1,4])
C0079744 (UMLS CUI [2,1])
C0040682 (UMLS CUI [2,2])
C3888518 (UMLS CUI [2,3])
C0432516 (UMLS CUI [2,4])
C0024301 (UMLS CUI [3,1])
C0432516 (UMLS CUI [3,2])
Ineligibility Autologous hematopoietic stem cell transplant | Autologous hematopoietic stem cell transplant Previous
Item
ineligible for or have previously received an autologous stem cell transplant (asct)
boolean
C1512714 (UMLS CUI [1,1])
C2193200 (UMLS CUI [1,2])
C2193200 (UMLS CUI [2,1])
C0205156 (UMLS CUI [2,2])
Recurrent disease Post Systemic Chemotherapy | Recurrent disease Post Autologous hematopoietic stem cell transplant
Item
relapsed following receipt of the last dose of systemic chemotherapy or asct
boolean
C0277556 (UMLS CUI [1,1])
C0687676 (UMLS CUI [1,2])
C1883256 (UMLS CUI [1,3])
C0277556 (UMLS CUI [2,1])
C0687676 (UMLS CUI [2,2])
C2193200 (UMLS CUI [2,3])
Prior Chemotherapy Quantity | Anthracyclines | Exception Anthracyclines Contraindicated
Item
at least one prior chemotherapy regimen. prior chemotherapy regimen must have contained anthracycline (unless contraindicated)
boolean
C1514457 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0282564 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0282564 (UMLS CUI [3,2])
C1444657 (UMLS CUI [3,3])
Gender | Pregnancy Absent | Breast Feeding Absent | Females & males of reproductive potential Sexually active Contraceptive methods
Item
if the subject is female, she must be non-pregnant and non-lactating at the baseline visit. all sexually active males and females of childbearing potential must agree to use an adequate method of contraception throughout the study period
boolean
C0079399 (UMLS CUI [1])
C0032961 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0006147 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C4034483 (UMLS CUI [4,1])
C0241028 (UMLS CUI [4,2])
C0700589 (UMLS CUI [4,3])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status </= 1
boolean
C1520224 (UMLS CUI [1])
Pharmacotherapy Standard Against Lymphoma | Pharmacotherapy Investigational Against Lymphoma
Item
use of any standard/experimental anti-lymphoma drug therapy within 21 days of the baseline visit
boolean
C0013216 (UMLS CUI [1,1])
C1442989 (UMLS CUI [1,2])
C0521124 (UMLS CUI [1,3])
C0024299 (UMLS CUI [1,4])
C0013216 (UMLS CUI [2,1])
C1517586 (UMLS CUI [2,2])
C0521124 (UMLS CUI [2,3])
C0024299 (UMLS CUI [2,4])
Systemic steroids | Exception Premedication
Item
use of systemic steroids within 5 days of the baseline visit (except for the purposes of pre-medication prior to study regimen treatment)
boolean
C2825233 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0033045 (UMLS CUI [2,2])
Allogeneic Stem Cell Transplantation Previous
Item
prior allogeneic stem cell transplant (sct)
boolean
C2242529 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
YM-155 Use of Previous
Item
the subject has been previously treated with ym155
boolean
C2002939 (UMLS CUI [1,1])
C1524063 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
HIV Seropositivity | Hepatitis B surface antigen positive | Hepatitis C antibody positive
Item
the subject has known human immunodeficiency virus (hiv), hepatitis b surface antigen, or hepatitis c antibody
boolean
C0019699 (UMLS CUI [1])
C0149709 (UMLS CUI [2])
C0281863 (UMLS CUI [3])
Therapies, Investigational | Procedures Investigational
Item
the subject has received other investigational therapy or procedures within 21 days prior to the first study drug administration
boolean
C0949266 (UMLS CUI [1])
C0184661 (UMLS CUI [2,1])
C1517586 (UMLS CUI [2,2])